inorelbine（VNR）の単剤療法

摘要

進行非小細胞肺癌（NSCLC）において，vinorelbine（VNR）単剤はold cisplatin-based doubletに比べ，ほぼ同等の効果を有し，明らかに毒性は軽い．また，高齢者ではbest supportive care（BSC）に比べ，有意に優れた生存とquality of life（QOL）の改善をもたらした．つまりVNR単剤はcisplatin（CDDP）を投与できない高齢者や状態不良な患者に対する治療選択肢のひとつと位置づけられる．一方，全身状態良好な進行NSCLCにはVNRとCDDPを併用することで，VNR単剤に比べ抗腫瘍効果の増強と生存期間の延長が期待できる．Vinorelbine monotherapy is as effective and clearly less toxic than old cisplatin-based doublet in patients with advanced non-small-cell lung cancer (NSCLC). Compared to the best supportive care, vinorelbine monotherapy has been shown to improve survival and quality of life in elderly patients with advanced NSCLC. Therefore, this monotherapy is considered the treatment of choice for elderly or frail patients who cannot tolerate cisplatin-containing regimens. In addition, the combination of vinorelbine plus cisplatin may be superior to vinorelbine alone in NSCLC patients with a good performance status both in terms of response rate and survival duration.